中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2012年
6期
11-13
,共3页
鼻咽肿瘤%吉西他滨%奈达铂%同期放化疗
鼻嚥腫瘤%吉西他濱%奈達鉑%同期放化療
비인종류%길서타빈%내체박%동기방화료
Nasopharyngeal neoplasms%Gemcitabine%Nedaplatin%Concurrent chemotherapy and radiotherapy
目的 观察吉西他滨联合奈达铂同期放化疗治疗晚期鼻咽癌的临床疗效.方法 将76例晚期鼻咽癌患者按随机数字表法分为两组,观察组38例采用吉西他滨联合奈达铂同期放化疗,对照组38例采用氟尿嘧啶联合顺铂同期放化疗,观察比较两组的临床疗效和不良反应.结果 观察组的总有效率为84.2％(32/38),明显高于对照组的60.5％(23/38),差异有统计学意义(P＜0.05).两组1年生存率比较差异无统计学意义[89.5％(34/38)比76.3％(29/38)](P＞ 0.05).观察组消化道反应发生率和口腔溃疡发生率分别为42.1％(16/38)和7.9％(3/38),均明显低于对照组的73.7％(28/38)、31.6％(12/38)(P＜ 0.05),而两组骨髓抑制发生率比较差异无统计学意义[31.6％(12/38)比23.7％(9/38)](P＞ 0.05).结论 吉西他滨联合奈达铂同期放化疗治疗晚期鼻咽癌,能够明显提高临床疗效,减少不良反应.
目的 觀察吉西他濱聯閤奈達鉑同期放化療治療晚期鼻嚥癌的臨床療效.方法 將76例晚期鼻嚥癌患者按隨機數字錶法分為兩組,觀察組38例採用吉西他濱聯閤奈達鉑同期放化療,對照組38例採用氟尿嘧啶聯閤順鉑同期放化療,觀察比較兩組的臨床療效和不良反應.結果 觀察組的總有效率為84.2％(32/38),明顯高于對照組的60.5％(23/38),差異有統計學意義(P＜0.05).兩組1年生存率比較差異無統計學意義[89.5％(34/38)比76.3％(29/38)](P＞ 0.05).觀察組消化道反應髮生率和口腔潰瘍髮生率分彆為42.1％(16/38)和7.9％(3/38),均明顯低于對照組的73.7％(28/38)、31.6％(12/38)(P＜ 0.05),而兩組骨髓抑製髮生率比較差異無統計學意義[31.6％(12/38)比23.7％(9/38)](P＞ 0.05).結論 吉西他濱聯閤奈達鉑同期放化療治療晚期鼻嚥癌,能夠明顯提高臨床療效,減少不良反應.
목적 관찰길서타빈연합내체박동기방화료치료만기비인암적림상료효.방법 장76례만기비인암환자안수궤수자표법분위량조,관찰조38례채용길서타빈연합내체박동기방화료,대조조38례채용불뇨밀정연합순박동기방화료,관찰비교량조적림상료효화불량반응.결과 관찰조적총유효솔위84.2％(32/38),명현고우대조조적60.5％(23/38),차이유통계학의의(P＜0.05).량조1년생존솔비교차이무통계학의의[89.5％(34/38)비76.3％(29/38)](P＞ 0.05).관찰조소화도반응발생솔화구강궤양발생솔분별위42.1％(16/38)화7.9％(3/38),균명현저우대조조적73.7％(28/38)、31.6％(12/38)(P＜ 0.05),이량조골수억제발생솔비교차이무통계학의의[31.6％(12/38)비23.7％(9/38)](P＞ 0.05).결론 길서타빈연합내체박동기방화료치료만기비인암,능구명현제고림상료효,감소불량반응.
Objective To observe the clinical effect of gemcitabine combined with nedaplatin concurrent chemotherapy and radiotherapy in treatment of advanced nasopharyngeal carcinoma.Methods Seventy-six advanced nasopharyngeal carcinoma patients were divided into observation group(38 cases)and control group(38 cases)by radom digits table.The patients in observation group were treated with gemcitabine combined with nedaplatin concurrent chemotherapy and radiotherapy.The patients in control group were treated with fluorouracil combined with cisplatin concurrent chemotherapy and radiotherapy.The clinical effect and adverse reaction were compared between two groups.Results The total effective rate in observation group was 84.2％(32/38),which significantly higher than that in control group[60.5％(23/38)](P＜0.05).There was no significant difference in 1 year overall survival rate between two groups[89.5％ (34/38)vs.76.3％(29/38)](P ＞ 0.05).The rate of gastrointestinal reactions and oral ulcers in observation group were 42.1％(16/38)and 7.9％(3/38),which significantly lower than those in control group[73.7％ (28/38),31.6％(12/38)](P ＜ 0.05).The rate of bone marrow suppression between two groups had no significant difference[31.6％(12/38)vs.23.7％(9/38)](P ＞ 0.05).Conclusion Gemcitabine combined with nedaplatin concurrent chemotherapy and radiotherapy in treatment of advanced nasopharyngeal carcinoma can enhance the clinical effect,and decrease the adverse reaction,which can be applied in clinic.
